# Estimating the societal cost of heroin dependence in an Australian population engaged in treatment



## <u>Natasha Hall<sup>1,2,3</sup></u>, Long Khanh-Dao Le<sup>3</sup>, Julie Abimanyi-Ochom<sup>1</sup>, Christina Marel<sup>4</sup>, Katherine Mills<sup>4</sup>, Maree Teesson<sup>4</sup>, Cathrine Mihalopoulos<sup>1</sup>

<sup>1</sup>Deakin Health Economics, Institute for Health Transformation, Deakin University, Melbourne, Australia

<sup>2</sup>Turning Point, Eastern Health, Melbourne, Victoria, Australia

<sup>3</sup> Monash University Health Economics Group, School of Public and Preventive Medicine, Monash University, Victoria, Australia

## **BACKGROUND**

- Opioid use disorder is a public health concern in Australia and internationally.<sup>1</sup>
- High mortality rates, increased risk of physical/mental health comorbidities and social issues contribute to a high personal and societal cost.<sup>2,3,4</sup>
- Little is known about the societal cost of heroin dependence in an Australian context.

## OBJECTIVE

The study aimed to determine annual per person societal costs of heroin dependence in an Australian population and to understand how these costs change over time.

Table 1. Included costs and categories

Healthcare costs		<b>Productivity costs</b>	Crime costs	Other costs
Health service use	<u>Heroin dependence</u>			
<u>costs</u>	treatment costs			
<ul> <li>General practitioner</li> <li>Hospital outpatient</li> <li>Specialist doctor</li> <li>Psychologist</li> <li>Psychiatrist</li> <li>Counsellor</li> <li>Social worker</li> <li>Alcohol/drug worker</li> <li>Radiology</li> <li>Blood/urine test</li> <li>Medication</li> <li>Hospital admission</li> <li>Emergency admission</li> <li>Ambulance</li> </ul>	<ul> <li>Inpatient detoxification</li> <li>Residential rehabilitation</li> <li>Methadone</li> <li>Outpatient withdrawal</li> <li>Buprenorphine maintenance/with drawal</li> <li>Naltrexone maintenance</li> <li>Drug and alcohol counselling</li> </ul>	<ul> <li>Lost         productivity due         to         unemployment</li> <li>Lost         productivity due         to illegal activity</li> <li>Lost         productivity due         to premature         death</li> </ul>	<ul> <li>Property crime</li> <li>Drug dealing</li> <li>Fraud</li> <li>Violent crime</li> </ul>	<ul> <li>Homelessne ss</li> <li>Cost of heroin</li> <li>Prison sentence</li> </ul>

### **METHOD**

- Data was obtained from the NSW component of the Australian Treatment Outcome Study, a longitudinal cohort study which began in 2001.<sup>5</sup>
- 600 individuals who were heroin dependent at baseline were interviewed at five time points – baseline, 12 months, 24 months, 36 months and 11 years.
- Resource use was determined from the interviews and was multiplied by unit costs to estimate the annual healthcare costs, productivity costs, crime costs and other costs. Table 1 shows the costs that were included.
- The monetary value of premature mortality was calculated using the value of a statistical life year method.<sup>6</sup>
- Sensitivity analyses were conducted, in which the mean ATOS annual sample costs were extrapolated to three different Australia wide heroin dependent populations.

### RESULTS

• The annual mean societal cost of heroin dependence for the ATOS sample over the 11 years was A\$139,213 (95% CI 127142, 151284), which included healthcare costs (A\$10,000), lost productivity costs (A\$23,082), crime costs (A\$73,172) and other costs (A\$34,576).

- Naloxone


- Healthcare costs, productivity costs, crime costs and other costs trended downwards over the five waves. Table 2 presents the specific results of the costs from baseline to 11 years.
- Crime was the highest cost contributor (52%), followed by heroin drug (22%) and lost productivity (16%). Figure 1 shows the distribution of the mean annual per person costs.
- The estimated number of life years lost over the 11-year study period due to heroin equalled 2,703 years, which approximates to a monetary value of premature death of \$213 million.

Table 2. Yearly mean costs per person in AUD

	Healthcare costs (95% CI) Standard error (SE)	Crime costs (95% CI) Standard error (SE)	Productivity costs income loss (95% CI) Standard error (SE)
		<b>237,474</b> (209246,	
Baseline	<b>12,917</b> (11712, 14123)	265702)	<b>34,041</b> (32732, 35350)
		<b>66,796</b> (51861,	
12-month	<b>12,588</b> (11455, 13662)	81731)	30,326 (29078, 31573)
		<b>38,693</b> (26080,	
24-month	<b>8,210</b> (7486, 8934)	51305)	<b>18,066</b> (16941, 19190)
		<b>31,639</b> (20663,	
36-month	<b>7,926</b> (7178, 8674)	42614)	<b>15,844</b> (14823, 16865)
		<b>26,241</b> (17436,	
11 year	<b>8,587</b> (7798, 9376)	35046)	<b>21,447</b> (20214, 22680)
Mean annual costs of		<b>73,172</b> (62,550,	
the 5 waves	<b>10,000</b> (9386, 10615)	83795)	<b>23,082</b> (22027, 24138)

Figure 1. Breakdown of the mean annual societal costs over the 5 waves

**Productivity costs** 



## CONCLUSION

\*addition of all costs does not equal total costs due to multiple imputation

- The significant societal cost of heroin dependence emphasises the importance of providing resources and attention to heroin dependence.
- All costs trended downwards from baseline to 11 years in this ATOS cohort, indicating that treatment for heroin dependence plays a role in reducing societal costs associated with heroin dependence.
- The cost of crime and heroin to the individuals contributed to over 70% of the total costs, highlighting that the illicit nature of the illness contributes to the high societal costs.

Corresponding author: Natasha Hall Email: Natasha.hall@monash.edu.au Phone number: 03 9903 0918

[1] Degenhardt L et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Psychiatry. 2018;5(12):987-1012. [2] Degenhardt L et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32-51 [3]Mathers BM et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. The Lancet. 2008;372(9651):1733-45. [4] Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug And Alcohol Dependence. 2019;197:78-82. [5] Ross J et al. The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug & Alcohol Review. 2005;24(5):411-8. [6] Abelson P. Establishing a monetary value for lives saved. Canberra, Department of Finance and Deregulation. 2008;5:2012.

<sup>&</sup>lt;sup>4</sup> Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, Australia